John G Ullman & Associates Inc. Raises Stake in Thermo Fisher Scientific Inc. $TMO

Key Points

• John G Ullman & Associates Inc. increased its stake in Thermo Fisher Scientific Inc. by 29.9% in Q2, owning 11,614 shares valued at approximately $4.7 million.
• Several hedge funds, including Brighton Jones LLC and GAMMA Investing LLC, have also raised their holdings in Thermo Fisher, indicating strong institutional interest in the company.
• Analysts have recently set new price targets for Thermo Fisher Scientific, with estimates ranging from $565 to $650, reflecting a consensus "Moderate Buy" rating.

John G Ullman & Associates Inc. lifted its stake in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 29.9% during the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 11,614 shares of the medical research company's stock after buying an additional 2,671 shares during the quarter. John G Ullman & Associates Inc.'s holdings in Thermo Fisher Scientific were worth $4,709,000 at the end of the most recent reporting period.

Several other hedge funds have also recently modified their holdings of TMO. Brighton Jones LLC lifted its holdings in shares of Thermo Fisher Scientific by 28.9% in the fourth quarter. Brighton Jones LLC now owns 4,409 shares of the medical research company's stock worth $2,293,000 after buying an additional 988 shares in the last quarter. Revolve Wealth Partners LLC lifted its holdings in shares of Thermo Fisher Scientific by 4.2% in the fourth quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company's stock worth $255,000 after buying an additional 20 shares in the last quarter. GAMMA Investing LLC lifted its holdings in shares of Thermo Fisher Scientific by 22.0% in the first quarter. GAMMA Investing LLC now owns 4,862 shares of the medical research company's stock worth $2,419,000 after buying an additional 877 shares in the last quarter. CWA Asset Management Group LLC lifted its holdings in shares of Thermo Fisher Scientific by 4.3% in the first quarter. CWA Asset Management Group LLC now owns 1,435 shares of the medical research company's stock worth $714,000 after buying an additional 59 shares in the last quarter. Finally, Blue Trust Inc. increased its position in Thermo Fisher Scientific by 22.0% in the first quarter. Blue Trust Inc. now owns 1,249 shares of the medical research company's stock worth $621,000 after purchasing an additional 225 shares during the last quarter. Hedge funds and other institutional investors own 89.23% of the company's stock.

Insider Transactions at Thermo Fisher Scientific

In other news, CAO Joseph R. Holmes sold 385 shares of the company's stock in a transaction dated Friday, August 29th. The shares were sold at an average price of $492.63, for a total value of $189,662.55. Following the transaction, the chief accounting officer directly owned 2,319 shares in the company, valued at approximately $1,142,408.97. This represents a 14.24% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP Gianluca Pettiti sold 400 shares of the company's stock in a transaction dated Friday, July 25th. The stock was sold at an average price of $479.98, for a total transaction of $191,992.00. Following the completion of the transaction, the executive vice president owned 22,367 shares in the company, valued at approximately $10,735,712.66. The trade was a 1.76% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 30,066 shares of company stock worth $14,182,963. Insiders own 0.33% of the company's stock.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on TMO shares. Evercore ISI boosted their price target on shares of Thermo Fisher Scientific from $525.00 to $590.00 and gave the stock an "outperform" rating in a research report on Tuesday, October 7th. Wells Fargo & Company reduced their price target on shares of Thermo Fisher Scientific from $570.00 to $565.00 and set an "overweight" rating on the stock in a research report on Thursday, July 24th. JPMorgan Chase & Co. boosted their price target on shares of Thermo Fisher Scientific from $600.00 to $650.00 and gave the stock an "overweight" rating in a research report on Thursday, October 9th. Robert W. Baird boosted their price objective on shares of Thermo Fisher Scientific from $553.00 to $567.00 and gave the company an "outperform" rating in a research report on Thursday, July 24th. Finally, Scotiabank upgraded shares of Thermo Fisher Scientific from a "sector perform" rating to a "sector outperform" rating and set a $590.00 price objective on the stock in a research report on Friday, July 11th. Fifteen equities research analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $589.10.

Thermo Fisher Scientific Trading Up 0.4%

NYSE TMO opened at $539.05 on Friday. The company's 50-day moving average price is $495.74 and its 200-day moving average price is $449.13. The company has a current ratio of 1.93, a quick ratio of 1.50 and a debt-to-equity ratio of 0.65. The stock has a market cap of $203.55 billion, a PE ratio of 31.18, a PEG ratio of 2.93 and a beta of 0.77. Thermo Fisher Scientific Inc. has a 12 month low of $385.46 and a 12 month high of $610.97.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its quarterly earnings results on Wednesday, July 23rd. The medical research company reported $5.36 EPS for the quarter, topping analysts' consensus estimates of $5.22 by $0.14. The firm had revenue of $10.86 billion for the quarter, compared to analysts' expectations of $10.68 billion. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The business's revenue for the quarter was up 2.9% on a year-over-year basis. During the same period in the prior year, the business posted $5.37 earnings per share. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. Equities research analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.